Alternative Excipients for Protein Stabilization in Protein Therapeutics: Overcoming the Limitations of PolysorbatesA. Ruiz, Alf Lamprecht, Julia Buske et al.|Pharmaceutics|2022Cited by 93
An in-depth examination of fatty acid solubility limits in biotherapeutic protein formulations containing polysorbate 20 and polysorbate 80Nils Glücklich, Patrick Garidel, Stefan Carle et al.|International Journal of Pharmaceutics|2020Cited by 47
Assessing the polysorbate degradation fingerprints and kinetics of lipases – how the activity of polysorbate degrading hydrolases is influenced by the assay and assay conditionsNils Glücklich, Patrick Garidel, Stefan Carle et al.|European Journal of Pharmaceutical Sciences|2021Cited by 37
Hydrolytic polysorbate 20 degradation – Sensitive detection of free fatty acids in biopharmaceuticals via UPLC-QDa analytics with isolator columnDirk-H. Evers, Julia Buske, Stefan Carle et al.|Journal of Chromatography B|2021Cited by 14
Existence of a superior polysorbate fraction in respect to protein stabilization and particle formation?Tim Diederichs, Patrick Garidel, Judith J. Mittag et al.|International Journal of Pharmaceutics|2023Cited by 14